Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (NASDAQ: PSTV) reported an oral plenary presentation at AANS (May 1-4, 2026) reviewing clinical and translational data for REYOBIQ (rhenium Re186 obisbemeda) in leptomeningeal metastases (LM).
Key points: Phase 1 ReSPECT-LM showed median overall survival ~9 months at the recommended Phase 2 dose versus historical ~2–6 months; robust circulating tumor cell reductions; favorable safety; target-to-off-target dose ratio >100:1. A multiple-dose Phase 1 trial is currently enrolling at UT Health San Antonio.
Plus Therapeutics (Nasdaq: PSTV) announced that subsidiary CNSide Diagnostics is enrolled in Medicare and received a Provider Transaction Access Number (PTAN), establishing the lab as Medicare‑enrolled for the CNSide® CSF Assay Platform including the tumor cell enumeration (TCE) test. Claims will be reimbursed if deemed reasonable and necessary by the local Medicare Administrative Contractor.
The company cited a pathway to ~35 million Medicare Advantage beneficiaries, existing ~81 million commercial covered lives, and a target of 150 million+ covered lives in 2026. A new CPT code 0640U is effective for billing July 1, 2026, with pricing via crosswalk or gapfill.
Plus Therapeutics (Nasdaq: PSTV) announced that Blue Shield of California will provide reimbursement for the CNSide® CSF Tumor Cell Enumeration assay, effective April 2026, expanding covered lives from ~75 million to ~81 million (+6 million).
The coverage aims to reduce reimbursement barriers, accelerate adoption across oncology centers, and advance the company’s 2026 objective of 150 million covered lives. CNSide reports >11,000 tests since 2020, sensitivity 92%, specificity 95%, and treatment decisions influenced in 90% of cases. Health economic analyses cited ~40% reduction in leptomeningeal metastases-related costs.
Plus Therapeutics (Nasdaq: PSTV) began manufacturing activities and technology transfer with SpectronRx under a Master Services Agreement to support GMP late-stage clinical supply of REYOBIQ and Rhenium-186.
The agreement adds SpectronRx as a second GMP site, centralizes isotope processing and drug manufacture in one Indiana facility, and aims to advance manufacturing scale-up toward a 2026 target milestone for late-stage clinical supply.
Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards to Eric J Daniels, M.D., who joined as Chief Development Officer on April 20, 2026. The awards include 20,000 stock options and 20,000 restricted stock units (RSUs), approved under Nasdaq Rule 5635(c)(4).
Options have a 10-year term with an exercise price of $7.30 (fair market value at grant). Options vest over four years; RSUs vest over three years, each subject to continued service.
Plus Therapeutics (Nasdaq: PSTV) announced it has regained compliance with Nasdaq's minimum bid price rule. Nasdaq confirmed the company's closing bid price was at or above $1.00 per share for 10 consecutive business days from April 6, 2026 to April 17, 2026.
Nasdaq advised the matter is closed, restoring full compliance with Listing Rule 5550(a)(2).
Plus Therapeutics (Nasdaq: PSTV) appointed Randy H. Goodman, PhD, MHA, as Vice President, Value Strategy & HEOR, effective April 13, 2026. Dr. Goodman brings 20+ years of payer strategy, HEOR, and policy experience to support CNSide adoption and commercialization of REYOBIQ.
The company granted inducement equity: 4,500 options (10-year term, $5.41 exercise) and 4,500 RSUs, with standard multi-year vesting schedules approved under Nasdaq Rule 5635(c)(4).
Plus Therapeutics (Nasdaq: PSTV) appointed Eric J. Daniels, M.D., MBA as Chief Development Officer, effective April 20, 2026. Dr. Daniels brings more than two decades of clinical development, regulatory strategy, and corporate operations experience to advance REYOBIQ and the company’s CNS-focused radiopharmaceutical pipeline.
The hire follows senior roles including CDO at Kiora Pharmaceuticals, co-founder of Bayon Therapeutics, and CEO of OccuRx, and is positioned to strengthen Plus’s development execution as it advances clinical programs.
Plus Therapeutics (Nasdaq: PSTV) announced the U.S. FDA granted Orphan Drug Designation to REYOBIQ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant gliomas, with the designation scope broadened to include progressive pediatric ependymoma. The company also noted FDA IND clearance for pediatric high-grade glioma and ependymoma and ongoing Phase 1/2 studies.
The designation offers potential benefits including seven years of market exclusivity, tax credits, and regulatory fee exemptions.
Plus Therapeutics (Nasdaq: PSTV) received an AMA PLA CPT code (0640U) for its CNSide® CSF Tumor Cell Enumeration (TCE) test, effective July 1, 2026.
This dedicated billing code establishes a unique reimbursement identifier to support payer claims processing, clinician adoption, national utilization tracking, and the Company’s ongoing U.S. commercial launch of CNSide diagnostics.